Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium.

Ricard N, Scott RP, Booth CJ, Velazquez H, Cilfone NA, Baylon JL, Gulcher JR, Quaggin SE, Chittenden TW, Simons M.

J Exp Med. 2019 Jun 13. pii: jem.20182151. doi: 10.1084/jem.20182151. [Epub ahead of print]

PMID:
31196980
2.

Enhancing Retrosynthetic Reaction Prediction with Deep Learning Using Multiscale Reaction Classification.

Baylon JL, Cilfone NA, Gulcher JR, Chittenden TW.

J Chem Inf Model. 2019 Feb 25;59(2):673-688. doi: 10.1021/acs.jcim.8b00801. Epub 2019 Feb 1.

PMID:
30642173
3.

Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.

Ayers KL, Glicksberg BS, Garfield AS, Longerich S, White JA, Yang P, Du L, Chittenden TW, Gulcher JR, Roy S, Fiedorek F, Gottesdiener K, Cohen S, North KE, Schadt EE, Li SD, Chen R, Van der Ploeg LHT.

J Clin Endocrinol Metab. 2018 Jul 1;103(7):2601-2612. doi: 10.1210/jc.2018-00258.

PMID:
29726959
4.

A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.

Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, Bai C, Rui L, Laleau R, Liu F, Ab O, Setiady Y, Yoder NC, Goldmacher VS, Chari RVJ, Pinkas J, Chittenden T.

Blood Adv. 2018 Apr 24;2(8):848-858. doi: 10.1182/bloodadvances.2018017517.

5.

Addendum: Shear-induced Notch-Cx37-p27 axis arrests endothelial cell cycle to enable arterial specification.

Fang JS, Coon BG, Gillis N, Chen Z, Qiu J, Chittenden TW, Burt JM, Schwartz MA, Hirschi KK.

Nat Commun. 2018 Feb 14;9(1):720. doi: 10.1038/s41467-018-03076-4. No abstract available.

6.

Shear-induced Notch-Cx37-p27 axis arrests endothelial cell cycle to enable arterial specification.

Fang JS, Coon BG, Gillis N, Chen Z, Qiu J, Chittenden TW, Burt JM, Schwartz MA, Hirschi KK.

Nat Commun. 2017 Dec 15;8(1):2149. doi: 10.1038/s41467-017-01742-7.

7.

Aging and neurodegeneration are associated with increased mutations in single human neurons.

Lodato MA, Rodin RE, Bohrson CL, Coulter ME, Barton AR, Kwon M, Sherman MA, Vitzthum CM, Luquette LJ, Yandava CN, Yang P, Chittenden TW, Hatem NE, Ryu SC, Woodworth MB, Park PJ, Walsh CA.

Science. 2018 Feb 2;359(6375):555-559. doi: 10.1126/science.aao4426. Epub 2017 Dec 7. Erratum in: Science. 2018 Jul 6;361(6397):.

8.

FGF-dependent metabolic control of vascular development.

Yu P, Wilhelm K, Dubrac A, Tung JK, Alves TC, Fang JS, Xie Y, Zhu J, Chen Z, De Smet F, Zhang J, Jin SW, Sun L, Sun H, Kibbey RG, Hirschi KK, Hay N, Carmeliet P, Chittenden TW, Eichmann A, Potente M, Simons M.

Nature. 2017 May 11;545(7653):224-228. doi: 10.1038/nature22322. Epub 2017 May 3.

9.

Cell types differ in global coordination of splicing and proportion of highly expressed genes.

Trakhtenberg EF, Pho N, Holton KM, Chittenden TW, Goldberg JL, Dong L.

Sci Rep. 2016 Aug 31;6:32249. doi: 10.1038/srep32249.

10.

Somatic mutation in single human neurons tracks developmental and transcriptional history.

Lodato MA, Woodworth MB, Lee S, Evrony GD, Mehta BK, Karger A, Lee S, Chittenden TW, D'Gama AM, Cai X, Luquette LJ, Lee E, Park PJ, Walsh CA.

Science. 2015 Oct 2;350(6256):94-98. doi: 10.1126/science.aab1785.

11.

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.

Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM.

Mol Cancer Ther. 2015 Jul;14(7):1605-13. doi: 10.1158/1535-7163.MCT-14-1095. Epub 2015 Apr 22.

12.

Proteomic analysis and identification of cellular interactors of the giant ubiquitin ligase HERC2.

Galligan JT, Martinez-Noël G, Arndt V, Hayes S, Chittenden TW, Harper JW, Howley PM.

J Proteome Res. 2015 Feb 6;14(2):953-66. doi: 10.1021/pr501005v. Epub 2014 Dec 15.

13.

Science and technology consortia in U.S. biomedical research: a paradigm shift in response to unsustainable academic growth.

Balch C, Arias-Pulido H, Banerjee S, Lancaster AK, Clark KB, Perilstein M, Hawkins B, Rhodes J, Sliz P, Wilkins J, Chittenden TW.

Bioessays. 2015 Feb;37(2):119-22. doi: 10.1002/bies.201400167. Epub 2014 Nov 12. No abstract available.

PMID:
25387399
14.

SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.

Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blanc V.

Clin Cancer Res. 2014 Sep 1;20(17):4574-83. doi: 10.1158/1078-0432.CCR-14-0695. Epub 2014 Jul 1.

15.

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.

Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, Mayo MF, Carrigan CN, Erickson HK, Pinkas J, Lutz RJ, Chittenden T, Lambert JM.

Blood. 2013 Nov 14;122(20):3500-10. doi: 10.1182/blood-2013-05-505685. Epub 2013 Sep 3.

16.

nEASE: a method for gene ontology subclassification of high-throughput gene expression data.

Chittenden TW, Howe EA, Taylor JM, Mar JC, Aryee MJ, Gómez H, Sultana R, Braisted J, Nair SJ, Quackenbush J, Holmes C.

Bioinformatics. 2012 Mar 1;28(5):726-8. doi: 10.1093/bioinformatics/bts011. Epub 2012 Jan 13.

PMID:
22247278
17.

Therapeutic implications of GIPC1 silencing in cancer.

Chittenden TW, Pak J, Rubio R, Cheng H, Holton K, Prendergast N, Glinskii V, Cai Y, Culhane A, Bentink S, Schwede M, Mar JC, Howe EA, Aryee M, Sultana R, Lanahan AA, Taylor JM, Holmes C, Hahn WC, Zhao JJ, Iglehart JD, Quackenbush J.

PLoS One. 2010 Dec 30;5(12):e15581. doi: 10.1371/journal.pone.0015581.

18.

Functional classification analysis of somatically mutated genes in human breast and colorectal cancers.

Chittenden TW, Howe EA, Culhane AC, Sultana R, Taylor JM, Holmes C, Quackenbush J.

Genomics. 2008 Jun;91(6):508-11. doi: 10.1016/j.ygeno.2008.03.002. Epub 2008 Apr 22.

19.

Synectin/syndecan-4 regulate coronary arteriolar growth during development.

Dedkov EI, Thomas MT, Sonka M, Yang F, Chittenden TW, Rhodes JM, Simons M, Ritman EL, Tomanek RJ.

Dev Dyn. 2007 Jul;236(7):2004-10.

20.

Unique cardiopulmonary exercise test responses in overweight middle-aged adults with obstructive sleep apnea.

Kaleth AS, Chittenden TW, Hawkins BJ, Hargens TA, Guill SG, Zedalis D, Gregg JM, Herbert WG.

Sleep Med. 2007 Mar;8(2):160-8. Epub 2007 Feb 1.

PMID:
17275399
21.

Transcriptional profiling in coronary artery disease: indications for novel markers of coronary collateralization.

Chittenden TW, Sherman JA, Xiong F, Hall AE, Lanahan AA, Taylor JM, Duan H, Pearlman JD, Moore JH, Schwartz SM, Simons M.

Circulation. 2006 Oct 24;114(17):1811-20. Epub 2006 Oct 16.

PMID:
17043168
22.

Synectin-dependent gene expression in endothelial cells.

Lanahan AA, Chittenden TW, Mulvihill E, Smith K, Schwartz S, Simons M.

Physiol Genomics. 2006 Nov 27;27(3):380-90. Epub 2006 Aug 29.

PMID:
16940428
23.

Selective regulation of arterial branching morphogenesis by synectin.

Chittenden TW, Claes F, Lanahan AA, Autiero M, Palac RT, Tkachenko EV, Elfenbein A, Ruiz de Almodovar C, Dedkov E, Tomanek R, Li W, Westmore M, Singh JP, Horowitz A, Mulligan-Kehoe MJ, Moodie KL, Zhuang ZW, Carmeliet P, Simons M.

Dev Cell. 2006 Jun;10(6):783-95.

24.

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blättler WA, Goldmacher VS.

Cancer Res. 2006 Mar 15;66(6):3214-21.

25.

Automated migration analysis based on cell texture: method & reliability.

Qin J, Chittenden TW, Gao L, Pearlman JD.

BMC Cell Biol. 2005 Mar 3;6(1):9.

26.

Characterization of synectin expression and promoter activity.

Zhang Y, Chittenden T, Simons M.

Gene. 2004 Nov 10;342(1):29-34.

PMID:
15527962
27.

Puma is an essential mediator of p53-dependent and -independent apoptotic pathways.

Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, McKinnon PJ, Cleveland JL, Zambetti GP.

Cancer Cell. 2003 Oct;4(4):321-8.

28.

An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.

Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, Singh R.

Cancer Res. 2003 Aug 15;63(16):5073-83.

29.
30.

p53 has a direct apoptogenic role at the mitochondria.

Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM.

Mol Cell. 2003 Mar;11(3):577-90.

31.

The pro-apoptotic protein, Bik, exhibits potent antitumor activity that is dependent on its BH3 domain.

Tong Y, Yang Q, Vater C, Venkatesh LK, Custeau D, Chittenden T, Chinnadurai G, Gourdeau H.

Mol Cancer Ther. 2001 Dec;1(2):95-102.

32.

BH3 domains: intracellular death-ligands critical for initiating apoptosis.

Chittenden T.

Cancer Cell. 2002 Sep;2(3):165-6. Review.

33.

Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals.

Han J, Flemington C, Houghton AB, Gu Z, Zambetti GP, Lutz RJ, Zhu L, Chittenden T.

Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11318-23.

34.

A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation.

Skaletskaya A, Bartle LM, Chittenden T, McCormick AL, Mocarski ES, Goldmacher VS.

Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7829-34. Epub 2001 Jun 26.

35.

Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155.

Zhou XM, Liu Y, Payne G, Lutz RJ, Chittenden T.

J Biol Chem. 2000 Aug 11;275(32):25046-51.

36.

ei24, a p53 response gene involved in growth suppression and apoptosis.

Gu Z, Flemington C, Chittenden T, Zambetti GP.

Mol Cell Biol. 2000 Jan;20(1):233-41.

37.

A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2.

Goldmacher VS, Bartle LM, Skaletskaya A, Dionne CA, Kedersha NL, Vater CA, Han JW, Lutz RJ, Watanabe S, Cahir McFarland ED, Kieff ED, Mocarski ES, Chittenden T.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12536-41.

38.
39.

Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria.

Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda H, Tsujimoto Y.

Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14681-6.

40.

The sepsis syndrome and the cancer patient: respiratory management and active physiotherapy.

Thompson N, Chittenden T.

Eur J Cancer Care (Engl). 1998 Jun;7(2):99-101. Review.

PMID:
9697451
41.

Gene structure, cDNA sequence, and expression of murine Bak, a proapoptotic Bcl-2 family member.

Ulrich E, Kauffmann-Zeh A, Hueber AO, Williamson J, Chittenden T, Ma A, Evan G.

Genomics. 1997 Sep 1;44(2):195-200.

PMID:
9299236
42.

Human Bak induces cell death in Schizosaccharomyces pombe with morphological changes similar to those with apoptosis in mammalian cells.

Ink B, Zörnig M, Baum B, Hajibagheri N, James C, Chittenden T, Evan G.

Mol Cell Biol. 1997 May;17(5):2468-74.

43.

Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells.

Lehar SM, Nacht M, Jacks T, Vater CA, Chittenden T, Guild BC.

Oncogene. 1996 Mar 21;12(6):1181-7.

PMID:
8649819
44.

A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions.

Chittenden T, Flemington C, Houghton AB, Ebb RG, Gallo GJ, Elangovan B, Chinnadurai G, Lutz RJ.

EMBO J. 1995 Nov 15;14(22):5589-96.

45.

Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins.

Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ, Ebb RG, Subramanian T, Chittenden T, Lutz RJ, et al.

Oncogene. 1995 Nov 2;11(9):1921-8.

PMID:
7478623
46.

Induction of apoptosis by the Bcl-2 homologue Bak.

Chittenden T, Harrington EA, O'Connor R, Flemington C, Lutz RJ, Evan GI, Guild BC.

Nature. 1995 Apr 20;374(6524):733-6.

PMID:
7715730
47.

E2F-4, a new member of the E2F transcription factor family, interacts with p107.

Ginsberg D, Vairo G, Chittenden T, Xiao ZX, Xu G, Wydner KL, DeCaprio JA, Lawrence JB, Livingston DM.

Genes Dev. 1994 Nov 15;8(22):2665-79.

48.
49.
50.

Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties.

Kaelin WG Jr, Krek W, Sellers WR, DeCaprio JA, Ajchenbaum F, Fuchs CS, Chittenden T, Li Y, Farnham PJ, Blanar MA, et al.

Cell. 1992 Jul 24;70(2):351-64.

PMID:
1638635

Supplemental Content

Loading ...
Support Center